FLT3 and acute myeloid leukemia: Preliminary results of a phase 2 trial in 28 r/r FLT3 mutated (ITD and TKD) AML (16 with prior FLT3 inhibitor exposure, 20 combined with IC, 8 combined with azacitidine) showed an ORR of 46% (including 10 cCR).